Physician profile
Scott E Spencer
NPI 1104864388
$1,664.45
in general payments reported to CMS, 2019-2025
19 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $332 · 2022: $27.77 · 2023: $44.39 · 2024: $90.15 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.75 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $281.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $174.58 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $169.19 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $146.18 | 2019-2020 | |
| Inspire Medical Systems, INC. | $125.27 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $103.26 | 2019-2020 | |
| Insmed, INC. | $89.21 | 2019-2020 | |
| Philips North America LLC | $59.90 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $55.19 | 2019 | |
| Boston Scientific Corporation | $50.80 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $37.40 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $33.54 | 2019-2020 | |
| Circassia INC. | $29.89 | 2019 | |
| Solventum Corporation | $28.15 | 2024 | V.A.C. Granufoam, Activ.A.C. |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $27.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.27 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $19.22 | 2025 | Lumryz |
| Shire North American Group INC | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.